[go: up one dir, main page]

AR014417A1 - LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE - Google Patents

LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE

Info

Publication number
AR014417A1
AR014417A1 ARP990100179A ARP990100179A AR014417A1 AR 014417 A1 AR014417 A1 AR 014417A1 AR P990100179 A ARP990100179 A AR P990100179A AR P990100179 A ARP990100179 A AR P990100179A AR 014417 A1 AR014417 A1 AR 014417A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
phenylmetile
penylmentil
pentaazatetradecanodioico
dimetiletil
Prior art date
Application number
ARP990100179A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR014417(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR014417A1 publication Critical patent/AR014417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sal de bisulfato cristalina de la formula (I) que tiene una velocidad de solubilidad disolucion inesperadamente alta y biodisponibilidad oral tambiénalta con relacion a la forma de base libre de este compuesto y composicion farmacéutica quel a comprende. Debido a dicha alta biodisponibilidad así comosu buena cristalinidad y estabilidad, la sal de bisulfato es muy util en la preparacion de formas de dosis orales. Esta sal de bisulfato, y formulacionesde la misma, se utilizan parael t ratamiento de enfermedades causadas por virus, especialmente retrovirus, como el HIV.
ARP990100179A 1998-01-20 1999-01-18 LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE AR014417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20

Publications (1)

Publication Number Publication Date
AR014417A1 true AR014417A1 (es) 2001-02-28

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100179A AR014417A1 (es) 1998-01-20 1999-01-18 LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE

Country Status (38)

Country Link
US (1) US6087383A (es)
EP (1) EP1056722B1 (es)
JP (2) JP4860037B2 (es)
KR (1) KR100559283B1 (es)
CN (1) CN1116282C (es)
AR (1) AR014417A1 (es)
AT (1) ATE219057T1 (es)
AU (1) AU735875B2 (es)
BG (1) BG64774B1 (es)
BR (1) BR9814736A (es)
CA (1) CA2317736C (es)
CO (1) CO4970820A1 (es)
CZ (1) CZ293507B6 (es)
DE (1) DE69806067T2 (es)
DK (1) DK1056722T3 (es)
EE (1) EE04434B1 (es)
EG (1) EG23936A (es)
ES (1) ES2178300T3 (es)
GE (1) GEP20033026B (es)
HU (1) HU227196B1 (es)
IL (2) IL137384A0 (es)
LT (1) LT4780B (es)
LV (1) LV12522B (es)
MY (1) MY114838A (es)
NO (1) NO315605B1 (es)
NZ (1) NZ504417A (es)
PE (1) PE20000185A1 (es)
PL (1) PL190744B1 (es)
PT (1) PT1056722E (es)
RO (1) RO118869B1 (es)
RU (1) RU2186070C2 (es)
SK (1) SK283975B6 (es)
TR (1) TR200001876T2 (es)
TW (1) TW531531B (es)
UA (1) UA59432C2 (es)
UY (1) UY25345A1 (es)
WO (1) WO1999036404A1 (es)
ZA (1) ZA9956B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012560A (es) 2000-06-30 2003-05-14 Elan Pharm Inc Compuestos para tratar la enfermedad de alzheimer.
JP2004534771A (ja) 2001-05-22 2004-11-18 イーラン　ファーマスーティカルズ、インコーポレイテッド アザヒドロキシル化エチルアミン化合物
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
EA201100293A1 (ru) * 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
PT2069303E (pt) * 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
ATE500820T1 (de) * 2007-06-22 2011-03-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
ATE503467T1 (de) * 2007-06-22 2011-04-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
ES2360336T3 (es) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
NZ582089A (en) * 2007-06-29 2013-01-25 Gilead Sciences Inc Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
US20110178305A1 (en) * 2008-05-08 2011-07-21 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
EP2391350A1 (en) 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
US8552036B2 (en) 2009-01-12 2013-10-08 Hetero Research Foundation Polymorph of atazanavir sulfate
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
BR112012009857A8 (pt) 2009-10-26 2023-04-11 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
EP2542527A2 (en) 2010-03-01 2013-01-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
EP2555757B1 (en) 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
WO2012041488A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US9382207B2 (en) 2012-08-24 2016-07-05 Laurus Labs Private Limited Process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
ZA201401073B (en) 2013-02-12 2015-12-23 Cipla Ltd Process for preparing atazanavir sulphate
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI933472A7 (fi) * 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
ATE219057T1 (de) 2002-06-15
TR200001876T2 (tr) 2000-11-21
EG23936A (en) 2008-01-14
TW531531B (en) 2003-05-11
IL137384A0 (en) 2001-07-24
CN1116282C (zh) 2003-07-30
SK283975B6 (sk) 2004-06-08
BR9814736A (pt) 2000-10-24
NZ504417A (en) 2001-09-28
EP1056722A1 (en) 2000-12-06
JP2009102357A (ja) 2009-05-14
CN1283188A (zh) 2001-02-07
KR20010034221A (ko) 2001-04-25
WO1999036404A1 (en) 1999-07-22
US6087383A (en) 2000-07-11
KR100559283B1 (ko) 2006-03-15
JP2002509136A (ja) 2002-03-26
EE200000798A (et) 2002-06-17
SK10622000A3 (sk) 2001-02-12
NO20003692D0 (no) 2000-07-19
DE69806067T2 (de) 2003-01-23
HU227196B1 (en) 2010-10-28
NO20003692L (no) 2000-07-19
HUP0101389A3 (en) 2003-07-28
CA2317736A1 (en) 1999-07-22
LV12522B (en) 2000-10-20
HK1033667A1 (en) 2001-09-14
CZ293507B6 (cs) 2004-05-12
HUP0101389A2 (hu) 2001-08-28
MY114838A (en) 2003-01-31
UA59432C2 (uk) 2003-09-15
EP1056722B1 (en) 2002-06-12
BG64774B1 (bg) 2006-03-31
PL190744B1 (pl) 2006-01-31
AU735875B2 (en) 2001-07-19
EE04434B1 (et) 2005-02-15
BG104618A (en) 2001-02-28
EP1056722A4 (en) 2001-01-10
CO4970820A1 (es) 2000-11-07
ZA9956B (en) 2000-07-05
DK1056722T3 (da) 2002-09-30
JP4860037B2 (ja) 2012-01-25
LT2000067A (en) 2000-11-27
PL342019A1 (en) 2001-05-07
CA2317736C (en) 2004-11-02
UY25345A1 (es) 2000-12-29
LV12522A (en) 2000-08-20
DE69806067D1 (de) 2002-07-18
LT4780B (lt) 2001-04-25
RU2186070C2 (ru) 2002-07-27
GEP20033026B (en) 2003-07-25
RO118869B1 (ro) 2003-12-30
HK1033458A1 (en) 2001-08-31
IL137384A (en) 2006-08-01
PE20000185A1 (es) 2000-05-14
CZ20002564A3 (cs) 2000-10-11
AU2010199A (en) 1999-08-02
NO315605B1 (no) 2003-09-29
PT1056722E (pt) 2002-09-30
ES2178300T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
AR014417A1 (es) LA SAL DE BISULFATO DEL ÉSTER DIMETíLICO DEL ÁCIDO[3S- (3R*, 8'R*, 9'R*, 12R*)] -3,12-BIS (1,1-DIMETILETIL) -8- HIDROXI-4,11- DIOXO-9- (FENILMETIL) -6- [[4-(2-PIRIDINIL) -FENILMETIL]] -2,5,6,10,13- PENTAAZATETRADECANODIOICO Y LA COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
BR0212069A (pt) Agentes antidiabéticos orais
NO894411D0 (no) Fremstilling av 3-piperidinyl-1,2-benzisoksazoler.
FR2356424A1 (fr) Compositions pharmaceutiques a base d'acide phophono-formique utiles pour lutter contre les infections virales
ES2196527T3 (es) Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
BRPI0116237B8 (pt) "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
BRPI0413469A (pt) derivados de piperazina para o tratamento de infecções por hiv
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DK625586A (da) Derivater af ((4-(4-(4-phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2-yl)methyl)-1h-imidazoler og -1h-1,2,4-triazoler
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
PT88577A (pt) Process for the manufacture of novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
FI861562A0 (fi) Substituerade n-/(4-piperidinyl) alkyl/-bicykliska kondenserade oxazol- och tiazolaminer.
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
FI913433A0 (fi) Foerfarande foer foerhindrande eller begraensande av skada vid aoterstroemning av blod genom ett organ eller en vaevnad.
PT1268407E (pt) Derivados de amidoxima de acido propenocarboxilico, um processo para a sua preparacao e composicoes farmaceuticas contendo os mesmos
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
ES2114722T3 (es) Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
RU2007132179A (ru) Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
DK0911026T3 (da) Creatinderivater for astma
AR011521A1 (es) Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
FG Grant, registration